Abstract
It is not surprising that the complex metabolic machinery of the gut microbiome has accidental, or directed, ability to alter our medicines and influence their efficacy. What is not known is the extent to which this has contributed to drug failures or contraindications, or to the derailment of clinical trials. Some studies are unraveling the mechanisms by which the microbiota alter specific drugs, such as digoxin, and contribute to variations in efficacies between patient populations. Microbiome profiling, therefore, may well become an inevitable arm of all clinical trials in the future.
Original language | English (US) |
---|---|
Journal | Gut microbes |
Volume | 4 |
Issue number | 5 |
DOIs | |
State | Published - Sep 2013 |
Keywords
- Digoxin
- Eggerthella lenta
- Medicines
- Microbiota
ASJC Scopus subject areas
- Microbiology
- Gastroenterology
- Microbiology (medical)
- Infectious Diseases